8-K: Incannex PSX-001 Phase 2 Trial Delivers Strong Results

Incannex Healthcare Inc. announced positive Phase 2 clinical trial results for PSX-001 (Psi-GAD), a psilocybin-assisted therapy for Generalised Anxiety Disorder.

Summary

• The Phase 2 clinical trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder (GAD) demonstrated statistically significant and clinically meaningful improvements across all key endpoints.
• The randomized, double-blind, placebo-controlled study enrolled 73 adult participants diagnosed with moderate to severe GAD.
• Participants received two dosing sessions with either a 25 mg dose of synthetic psilocybin or placebo, integrated with a proprietary psychotherapeutic protocol.
• The primary endpoint, HAM-A scores, showed an average 12.8-point reduction from baseline in the Psi-GAD group, compared to a 3.6-point reduction in the placebo group (p<0.0001), with effects sustained over 11 weeks.
• 44.1% of Psi-GAD patients achieved a clinical response (50% reduction in HAM-A score), more than four times higher than the placebo group.
• 27% of Psi-GAD patients achieved full disease remission (HAM-A ≤ 7), five times higher than placebo.
• Statistically significant improvements were also observed in secondary endpoints: GAD-7 (7.4-point reduction vs. 3.5 for placebo, p<0.0004), SDS (6.0-point reduction vs. 1.3 for placebo, p<0.007), PHQ-9 (3.9-point reduction vs. 0.3 for placebo, p<0.005), and PWI (10.6-point improvement vs. 2.7 for placebo, p<0.002).
• The treatment was well tolerated, with no serious adverse events (SAEs) reported and only one subject withdrawal out of 73. No signs of increased suicidality, psychosis, or prolonged psychological distress were observed.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive Phase 2 clinical trial results for a key drug candidate, demonstrating strong efficacy and safety across multiple measures, positioning it as a global leader in its class. This significantly de-risks a lead asset and validates the company's strategy, indicating a very strong positive outlook.

Positives

• PSX-001 achieved statistically significant and clinically meaningful improvements across all primary and secondary endpoints for Generalised Anxiety Disorder.
• Patients treated with Psi-GAD experienced an average 12.8-point reduction in HAM-A scores, significantly outperforming the placebo group's 3.6-point reduction (p<0.0001).
• A clinical response (50% HAM-A reduction) was observed in 44.1% of Psi-GAD patients, over four times higher than the placebo group.
• Full disease remission (HAM-A ≤ 7) was achieved by 27% of Psi-GAD patients, five times higher than placebo.
• Significant improvements were also noted in functional impairment (SDS), antidepressant effects (PHQ-9), and quality of life (PWI).
• The treatment effect was durable, sustained across the 11-week follow-up period.
• Psi-GAD demonstrated an excellent safety profile with no serious adverse events, only one withdrawal, and no signs of increased suicidality, psychosis, or prolonged psychological distress.
• The company has delivered back-to-back positive Phase 2 results for both PSX-001 and IHL-42X, significantly de-risking its lead assets and validating its development strategy.

Risks

• Current expense and cash resource estimates may be inaccurate, potentially requiring capital raises sooner than presently anticipated.
• The continued availability of financing is uncertain.
• The company's ability to raise capital to fund continuing operations and maintain or potentially further improve its capital structure is a risk.
• Maintaining the listing of common stock on the Nasdaq Stock Market is subject to ongoing compliance.
• The company faces potential impacts from infringement actions or other litigation.
• Success of development efforts, including progressing drug candidates through clinical trials on expected timelines and obtaining necessary regulatory approvals, is not guaranteed.
• Competition from other existing or future providers and products could affect market share.
• The market for drug candidates may not grow at anticipated rates or at all, and market estimates may prove incorrect.
• The company may be unable to successfully execute upon any commercial discussions.
• Compliance with various evolving and complex laws and regulations applicable to its business and industry poses a challenge.
• The company's ability to protect its proprietary technology and intellectual property is crucial for long-term success.

Future Outlook

The company plans to initiate a multi-jurisdiction Phase 2 clinical trial for PSX-001, leveraging its open Investigational New Drug (IND) application with the U.S. FDA. Concurrently, Incannex will refine formulation strategies to strengthen its intellectual property position and explore strategic partnerships to accelerate development and broaden global access to PSX-001 for patients with unmet needs.

Management Comments

• "These results speak for themselves—statistically significant, clinically meaningful, and consistent across every validated measure. Psi-GAD demonstrated a reduction in anxiety, improved mood, enhanced quality of life, and better day-to-day functioning. Importantly, the treatment effect was durable and observed across 11 weeks. These outcomes reinforce the power of our proprietary psychotherapeutic model and position Psi-GAD as a global leader in anxiety treatment innovation." Dr. Lou Barbato, Chief Medical Officer of Incannex.
• "We are also very pleased with the safety profile of Psi-GAD, particularly when considered alongside comparator programs in the market, which strengthens our confidence in both the clinical utility and scalability of this treatment." Dr. Lou Barbato, Chief Medical Officer of Incannex.
• "These are outstanding results for Incannex and a major milestone for our clinical pipeline. Alongside our strong cash position, the success of PSX-001 significantly de-risks another of our lead assets and further validates our strategy of developing innovative combination and psychedelic-based therapies." Joel Latham, President and Chief Executive Officer of Incannex.
• "To deliver back-to-back positive Phase 2 results for both PSX-001 and IHL-42X is an exceptional achievement, and one that gives us tremendous confidence as we progress towards late-stage development and continue to build value for patients and shareholders alike." Joel Latham, President and Chief Executive Officer of Incannex.

Industry Context

The positive Phase 2 results for PSX-001 position Incannex as a significant player in the emerging field of psychedelic-assisted therapies, particularly for Generalised Anxiety Disorder. This development offers a novel treatment option in a market where existing pharmaceutical interventions may have limitations or inadequate efficacy for some patients. The strong safety profile reported could provide a competitive advantage against other developing psychedelic treatments, enhancing its potential for broader adoption and market penetration.

Comparison to Industry Standards

• Psi-GAD demonstrated a reduction in anxiety scores to a greater extent than that reported for approved anxiety medications (as indicated in Figure 3 of the press release).
• The safety profile of Psi-GAD is considered strong, particularly when compared alongside comparator programs in the market, reinforcing confidence in its clinical utility and scalability.
• PSX-001 is established as a leading psilocybin-assisted therapy in development globally, indicating its competitive standing among other treatments in the pipeline.

Stakeholder Impact

• Shareholders: The positive Phase 2 results for PSX-001 significantly de-risk a lead asset and validate the company's strategic approach, potentially building long-term shareholder value.
• Patients with Generalised Anxiety Disorder: PSX-001 offers a promising, potentially best-in-class therapy with statistically significant and clinically meaningful improvements in anxiety, mood, disability, and quality of life.
• Investment Professionals: The strong clinical data provides compelling evidence for the potential of Incannex's pipeline and its position in the psychedelic-assisted therapy market.
• Regulatory Authorities: The robust efficacy and safety profile demonstrated in the Phase 2 trial will be crucial for future regulatory submissions and approvals.

Next Steps

• Initiate a multi-jurisdiction Phase 2 clinical trial for PSX-001, leveraging an open Investigational New Drug (IND) application with the U.S. FDA.
• Refine formulation strategies to ensure a robust and defensible intellectual property (IP) position for PSX-001.
• Explore strategic partnerships to accelerate development and broaden global access to PSX-001 for patients with unmet needs.

Key Dates

Recommendation

The overwhelmingly positive Phase 2 clinical trial results for PSX-001, demonstrating significant efficacy and a strong safety profile for Generalised Anxiety Disorder, represent a major de-risking event for Incannex's pipeline. The data positions PSX-001 as a global leader in psychedelic-assisted therapy for GAD, with potential to address a significant unmet medical need. This success, coupled with previous positive Phase 2 results for IHL-42X, validates the company's development strategy and significantly enhances its long-term value proposition, making it a compelling investment opportunity.

Keywords

psilocybin, Generalised Anxiety Disorder, GAD, PSX-001, Psi-GAD, Incannex Healthcare, clinical trial, Phase 2, mental health, psychedelic therapy, HAM-A, GAD-7, SDS, PHQ-9, PWI, anxiety treatment